<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036634</url>
  </required_header>
  <id_info>
    <org_study_id>GS-120-1101</org_study_id>
    <nct_id>NCT00036634</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients</brief_title>
  <official_title>A Phase 1/2, Randomized, Double-Blind, Active Controlled, Dose Escalation Study of the Safety, Tolerance, Pharmacokinetic,, and Antiviral Activity of GS-7340-02 in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate
      (tenofovir DF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted average change from baseline through Week 2 (DAVG2) for HIV-1 RNA (log10 copies/mL)</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>DAVG2 was defined as the time-weighted average between baseline value through the last available value up to week 2 minus the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HIV-1 RNA (log10 copies/mL)</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CD4 cell count (cells/mm3)</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Tenofovir DF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received tenofovir DF 300 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir alafenamide 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received tenofovir alafenamide 50 mg for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir alafenamide 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received tenofovir alafenamide 150 mg for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir DF</intervention_name>
    <description>Tenofovir DF tablet administered orally once daily</description>
    <arm_group_label>Tenofovir DF</arm_group_label>
    <other_name>VireadÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide</intervention_name>
    <description>Tenofovir alafenamide tablet(s) administered orally once daily</description>
    <arm_group_label>Tenofovir alafenamide 50 mg</arm_group_label>
    <arm_group_label>Tenofovir alafenamide 150 mg</arm_group_label>
    <other_name>GS-7340</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  HIV-1 RNA levels greater than or equal to 30,000 copies/mL

          -  CD4 count greater than or equal to 200 cells/mm3

          -  Serum creatinine &lt;1.5 mg/dl

          -  Hepatic transaminases less than or equal to 2.5 times the upper limit of normal

          -  Total bilirubin less than or equal to 1.5 mg/dL

          -  Adequate hematologic function

          -  Serum amylase less than or equal to 1.5 times the upper limit of normal

          -  Serum phosphate greater than or equal to 2.2 mg/dL

          -  Not pregnant

        Exclusion Criteria

          -  Prior treatment with antiretroviral therapy

          -  Immunization within 30 days of study entry

          -  A new AIDS defining condition within 30 days of study entry

          -  Receiving nephrotoxic agents, probenecid, chemotherapeutic agents, corticosteroids,
             interleukin-2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford Positive Care Program</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protocare Trials Chicago Center for Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockefeller University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2002</study_first_submitted>
  <study_first_submitted_qc>May 13, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2002</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

